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Pazopanib is a new cancer drug that works by limiting
the growth of new blood vessels in tumours. About half
of patients who take pazopanib develop high blood pres-
sure (hypertension). This side effect can make patients
have to reduce or stop their cancer treatment, and can
cause other health problems.
Understanding how pazopanib causes high blood pres-
sure will help us to advise doctors how to treat the high
blood pressure effectively, so that patients can continue
to take their cancer treatment safely. A proposed expla-
nation is that hypertension is caused by endothelial dys-
function as a consequence of reduced nitric oxide (NO)
bioavailability.
The aim of a study (HYPAZ) is to investigate the rela-
tionship between blood pressure and NO bioavailability
in cancer patients treated with pazopanib, who develop
hypertension. The predictor variable observed is the
change in blood pressure from baseline. The response
variable will be change in NO bioavailability measured
through the change in forearm blood flow ratio (of
infused versus control forearm) in response to intra-
arterial acetylcholine infusion. These data will give a
greater understanding to aspects of pazopanib’s mechan-
ism and relationship to hypertension. The primary analy-
sis for the study is to model and quantify the relationship
between NO bioavailability and blood pressure.
In planning the study there is little ap r i o r ievidence
to suggest the shape, nor to quantify the strength, of
any relationship. Hence an adaptive design is proposed
t oa s s e s st h ee v i d e n c ef o ra n yr e l a t i o n s h i pa n dj u d g e
possible sample size revisions at an interim analysis. To
perform model selection at an interim analysis is a
novel feature of this adaptive design. We consider some
of the operating characteristics of the proposed design.
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